Compare HFFG & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HFFG | SKYE |
|---|---|---|
| Founded | 1997 | 2012 |
| Country | United States | United States |
| Employees | 960 | N/A |
| Industry | Food Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.8M | 27.1M |
| IPO Year | 2016 | 2013 |
| Metric | HFFG | SKYE |
|---|---|---|
| Price | $1.87 | $0.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $6.00 | ★ $15.00 |
| AVG Volume (30 Days) | 97.1K | ★ 184.0K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.65 | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $1,228,282,000.00 | N/A |
| Revenue This Year | $5.59 | N/A |
| Revenue Next Year | $2.24 | N/A |
| P/E Ratio | $94.50 | ★ N/A |
| Revenue Growth | ★ 2.21 | N/A |
| 52 Week Low | $1.38 | $0.57 |
| 52 Week High | $3.86 | $5.75 |
| Indicator | HFFG | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 48.87 | 41.93 |
| Support Level | $1.75 | $0.70 |
| Resistance Level | $2.30 | $0.84 |
| Average True Range (ATR) | 0.09 | 0.06 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 45.00 | 15.56 |
HF Foods Group Inc is an Asian food service distributor that markets and distributes fresh produce, frozen and dry food, and non-food products to Asian restaurants and other foodservice customers throughout the United States. The company's business consists of one operating segment: HF Group, which operates solely in the United States. The company's product list consists of Meat, Poultry & Seafood, Sauces & Oils, Takeout Items (Boxes, Chopsticks & Utensils), Raw Ingredients (Flour, Cornstarch, Spices), Cleaning Supplies, and Rice & Grains.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.